# Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

> **NCT03164928** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 24 (actual)

## Conditions studied

- Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With
- Glucocorticoid-induced Osteoporosis

## Interventions

- **DRUG:** Denosumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03164928
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-07
- **Primary completion:** 2021-12-13
- **Final completion:** 2023-12-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164928, "Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03164928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*